Pyxis Oncology
1.14
Open
Market Cap
High
Low
Close
Volume
P/E Ratio
Div/Yield
About Pyxis Oncology
Pyxis Oncology, Inc. was incorporated in Delaware on June 11, 2018. As a clinical-stage oncology company, Pyxis Oncology is dedicated to developing next-generation multimodal therapeutic combinations aimed at tackling hard-to-treat cancers while improving patient quality of life. Its pipeline candidates are designed not only to directly kill tumor cells but also to address the underlying pathological processes of cancer, such as uncontrolled proliferation and immune evasion. For more information, visit the company’s website at http://www.pyxisoncology.com. Company Address: 321 Harrison Avenue Boston, Massachusetts 02118
Trade GPT
Similar Stocks
© Rockalpha Limited. All Rights Reserved.
Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider. Rockalpha Limited is not licensed by a New Zealand regulator to provide the client money or property services, and Rockalpha Limited’s registration on the New Zealand register of financial service providers or membership of the Insurance & Financial Services Ombudsman Scheme does not mean that Rockalpha Limited is subject to active regulation or oversight by a New Zealand regulator.Rockalpha Limited is registered on the New Zealand Financial Service Providers Register(FSP: 1001454). Rockalpha Limited's Financial Service Providers registration can be verified on the Financial Service Providers Register. Rockalpha Limited is a member of the Insurance & Financial Services Ombudsman Scheme, an independent dispute resolution service provider.